Connect with us

Drug maker with St. Pete plant makes a $1B buy

April 15, 2019 - Catalent Inc. agreed to buy Paragon Bioservices for $1.2 billion. Catalent (NYSE: CTLT) is a contract drug manufacturer; its St. Petersburg plant is its primary softgel development and manufacturing facility in North America. Paragon Bioservices is a biotech company that manufactures gene therapies for clinical and commercial use.

More Zaps Frontpage

The St. Pete Catalyst

The Catalyst honors its name by aggregating & curating the sparks that propel the St Pete engine.  It is a modern news platform, powered by community sourced content and augmented with directed coverage.  Bring your news, your perspective and your spark to the St Pete Catalyst and take your seat at the table.

Email us:

Subscribe for Free

Share with friend

Enter the details of the person you want to share this article with.